A Phase 2/3 interventional study of BCD-033 (interferon beta 1a) and Rebif (interferon beta 1a) in Multiple Sclerosis, sponsored by Biocad. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-02-17.
Sponsored by Biocad · Phase 2/3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 9th largest by enrollment, is the only one that started in 2015, is the only one in phase 2/3, and was the 34th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 8 · Phase 4 15
First in 1999; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 85 across the 34 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 34 have an industry lead sponsor. The 10 most frequent:
Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.
Biocad has 6 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with the use of active comparator and placebo. Total duration of therapy of about 2 years. Study hypothesis is equivalence of efficacy and safety of the investigational drug BCD-033 original drug Rebif®.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
Drug: BCD-033 (interferon beta 1a)
Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks, followed by 48 weeks of open-label BCD-033 usage
Drug: Rebif (interferon beta 1a)
Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for 48 weeks, followed by 72 weeks of open-label BCD-033 usage
Drug: Placebo
Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks
Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
Number of Combined Unique Active Lesions
Number of Combined Unique Active Lesions (CUA) -- the number of new MRI contrast uptake lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice) after 52 weeks blinded application of interferon-β1а (BCD-033 and Rebif®) (44 mcg).
Time frame: 52 weeks
Annual Relapse Rate
Annual relapse rate ARR for 52 weeks was evaluated in all three groups, after the application of IFN beta-1a
Time frame: 52 weeks
Proportion of Subjects Without Confirmed Relapse
proportion of subjects without confirmed relapse in PP
Time frame: 16, 52 weeks
Relapse Free Time
Time to first relapse in "per protocol" population
Time frame: 96 weeks
Number of Combined Unique Active Lesions
CUA (the number of new contrast-enhanced lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice)
Time frame: 96 weeks
Annual Relapse Rate
Annual Relapse Rate ARR for 96 weeks was evaluated in two groups, after the administraion of IFN beta-1a in a full dose for 96 weeks.
Time frame: 96 week
Relapse Free Time
Time to first relapse in "per protocol" population
Time frame: 16, 52 weeks
Number of Combined Unique Active Lesions
CUA (the number of new contrast-enhanced lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice).
Time frame: 16 weeks
Adverse Events/Serious Adverse Events
quantity and grade of all AE/SAE is calculated in subjects, who received at least one dose of study drug
Time frame: 96 weeks
Severe Adverse Events Frequency
AE grade 3-4 (CTCAE 4.03) is calculated in subjects, who received at least one dose of study drug
Time frame: 52 weeks
Withdrawal
quantity of withdrawals due to AE/SAE is calculated in subjects, who received at least one dose of study drug
Time frame: 16, 52 weeks
Immunogenicity
Count of Participants with Binding and Neutralizing Antibodies
Time frame: 16, 52 weeks
Adverse Reaction/Serious Adverse Reactions
quantity and grade of all adverse reactions/serious adverse reactions is calculated in subjects, who received at least one dose of study drug
Time frame: 16, 52 weeks
Severe Adverse Events Frequency
AE grade 3-4 (CTCAE 4.03)is calculated in subjects, who received at least one dose of study drug
Time frame: 96 weeks
Withdrawal
quantity of withdrawals due to AE/SAE is calculated in subjects, who received at least one dose of study drug
Time frame: 96 weeks
Immunogenicity
Count of Participants with Binding and Neutralizing Antibodies
Time frame: 96 weeks
Serious Adverse Events
quantity and grade of all SAE is calculated in subjects, who received at least one dose of study drug
Time frame: 52 week of study
| Milestone | BCD-033 | Rebif/BCD-033 | Placebo/BCD-033 |
|---|---|---|---|
| Started | 53 | 56 | 54 |
| Recived one injection of drug | 53 | 55 | 54 |
| Completed | 40 | 43 | 43 |
| Not completed | 13 | 13 | 11 |
Number of Combined Unique Active Lesions (CUA) -- the number of new MRI contrast uptake lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice) after 52 weeks blinded application of interferon-β1а (BCD-033 and Rebif®) (44 mcg).
| lesions | BCD-033 | Rebif |
|---|---|---|
| Number of Combined Unique Active Lesions | 0.0 (0.0 to 1.25) | 0.0 (0.0 to 1.0) |
Annual relapse rate ARR for 52 weeks was evaluated in all three groups, after the application of IFN beta-1a
| relapses | BCD-033 | Rebif / BCD-033 | Placebo / BCD-033 |
|---|---|---|---|
| Annual Relapse Rate | 0.113 ± 0.375 | 0.091 ± 0.348 | 0.109 ± 0.369 |
proportion of subjects without confirmed relapse in PP
| Count of Participants | BCD-033 | Rebif | Placebo |
|---|---|---|---|
| week 16 | 49 | 46 | 45 |
| week 52 | 41 | 44 | 39 |
Time to first relapse in "per protocol" population
| days | BCD-033 | Rebif/BCD-033 |
|---|---|---|
| Relapse Free Time | 207.0 (52.0 to 276.0) | 183.0 (26.0 to 286.0) |
CUA (the number of new contrast-enhanced lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice)
| lesions | BCD-033 | Rebif/BCD-033 |
|---|---|---|
| Number of Combined Unique Active Lesions | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) |
Annual Relapse Rate ARR for 96 weeks was evaluated in two groups, after the administraion of IFN beta-1a in a full dose for 96 weeks.
| relapses | BCD-033 | Rebif |
|---|---|---|
| Annual Relapse Rate | 0.208 ± 0.532 | 0.145 ± 0.524 |
Time to first relapse in "per protocol" population
| days | BCD-033 | Rebif | Placebo/BCD-033 |
|---|---|---|---|
| week 16 | 33.5 (12.0 to 60.0) | 14.0 (12 to 26.0) | 15.0 (5.0 to 61.75) |
| week 52 | 193.0 (51.5 to 240.0) | 123.5 (22.5 to 204.75) | 74.0 (25.0 to 210.0) |
CUA (the number of new contrast-enhanced lesions on T1 images, and new or expanding lesions on T2 images (lesion identified on T1-and T2 images is not counted twice).
| lesions | BCD-033 | Rebif | Placebo |
|---|---|---|---|
| Number of Combined Unique Active Lesions | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 1.0) | 1.0 (0.0 to 3.0) |
quantity and grade of all AE/SAE is calculated in subjects, who received at least one dose of study drug
| adverse events | BCD-033 | Rebif/BCD-033 |
|---|---|---|
| Adverse Events/Serious Adverse Events | 124 | 110 |
AE grade 3-4 (CTCAE 4.03) is calculated in subjects, who received at least one dose of study drug
| adverse events | BCD-033 | Rebif | Placebo/BCD-033 |
|---|---|---|---|
| Severe Adverse Events Frequency | 5 | 4 | 7 |
quantity of withdrawals due to AE/SAE is calculated in subjects, who received at least one dose of study drug
| Participants | BCD-033 | Rebif | Placebo/BCD-033 |
|---|---|---|---|
| week 16 | 0 | 1 | 1 |
| week 52 | 1 | 1 | 2 |
Count of Participants with Binding and Neutralizing Antibodies
| participants | BCD-033 | Rebif/BCD-033 | Placebo/BCD-033 |
|---|---|---|---|
| week 16 : Binding Antibodies | 6 | 5 | 2 |
| week 16 : Neutralizing Antibodies | 5 | 5 | 2 |
| week 52 : Binding Antibodies | 10 | 9 | 7 |
| week 52 : Neutralizing Antibodies | 9 | 8 | 7 |
quantity and grade of all adverse reactions/serious adverse reactions is calculated in subjects, who received at least one dose of study drug
| adverse events | BCD-033 | Rebif | Placebo/BCD-033 |
|---|---|---|---|
| week 16 | 67 | 59 | 33 |
| week 52 | 92 | 80 | 92 |
AE grade 3-4 (CTCAE 4.03)is calculated in subjects, who received at least one dose of study drug
| adverse events | BCD-033 | Rebif/BCD-033 |
|---|---|---|
| Severe Adverse Events Frequency | 2 | 3 |
quantity of withdrawals due to AE/SAE is calculated in subjects, who received at least one dose of study drug
| Participants | BCD-033 | Rebif/BCD-033 |
|---|---|---|
| Withdrawal | 1 | 1 |
Count of Participants with Binding and Neutralizing Antibodies
| participants | BCD-033 | Rebif/BCD-033 |
|---|---|---|
| Binding Antibodies | 19 | 14 |
| Neutralizing Antibodies | 16 | 13 |
quantity and grade of all SAE is calculated in subjects, who received at least one dose of study drug
| adverse events | BCD-033 | Rebif/BCD-033 | Placebo/BCD-033 |
|---|---|---|---|
| Serious Adverse Events | 0 | 0 | 3 |
Collected over 52 week. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BCD-033 | 0/53 (0%) | 0/53 (0%) | 35/53 (66%) |
| Rebif | 0/55 (0%) | 0/55 (0%) | 32/55 (58.2%) |
| Placebo/BCD-033 | 0/54 (0%) | 2/54 (3.7%) | 34/54 (63%) |
| Event | BCD-033 | Rebif | Placebo/BCD-033 |
|---|---|---|---|
| nephrotic syndromeRenal and urinary disorders | 0/53 | 0/55 | 1/54 |
| Left hemophthalmosEye disorders | — | — | 1/54 |
| Chronic viral hepatitis BInfections and infestations | — | — | 1/54 |
| Event | BCD-033 | Rebif | Placebo/BCD-033 |
|---|---|---|---|
| flu-like syndromGeneral disorders | 15/53 | 16/55 | 19/54 |
| local reactionGeneral disorders | 15/53 | 12/55 | 10/54 |
| neutropeniaInvestigations | 11/53 | 4/55 | 10/54 |
| feverGeneral disorders | 7/53 | 6/55 | 6/54 |
| lymphopeniaInvestigations | 5/53 | 4/55 | 4/54 |
| thrombocytopeniaInvestigations | 3/53 | 5/55 | 3/54 |
| increased ALTInvestigations | 3/53 | 4/55 | 3/54 |
| headacheGeneral disorders | 3/53 | 3/55 | 3/54 |
| Age, Categorical(Participants) | BCD-033 | Rebif / BCD-033 | Placebo / BCD-033 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 53 | 55 | 54 | 162 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | BCD-033 | Rebif / BCD-033 | Placebo / BCD-033 | Total |
|---|---|---|---|---|
| Median | 28.00 (25.00 to 39.0) | 30.00 (26.0 to 37.0) | 29.5 (26.0 to 38.0) | 29.0 (26.0 to 38.0) |
| Sex: Female, Male(Participants) | BCD-033 | Rebif / BCD-033 | Placebo / BCD-033 | Total |
|---|---|---|---|---|
| Female | 38 | 31 | 34 | 103 |
| Male | 15 | 24 | 20 | 59 |
Ran from Feb 2015 to primary completion in Nov 2016, 21 months.
Results were first posted in Feb 2023, 6 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a